We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Helps Patients with Risk of Heart Disease

By LabMedica International staff writers
Posted on 28 Mar 2013
A simple screening blood test and management program can be effective in preventing heart failure for at-risk patients.

Blood levels of B-type natriuretic peptide (BNP), a hormone that indicates how well the heart is functioning and elevated BNP levels can indicate established heart failure.

Cardiologists at St. More...
Vincent's University Hospital (Dublin, Ireland) recruited 1,374 patients from 39 family practices as part of a five-year study. The participants were asymptomatic patients over 40 years of age with risk factors for heart failure and randomized into an intervention and a control group. Patients in the intervention group were screened for blood levels of BNP, at least annually and all patients were screened for cardiovascular risk factors.

Of the patients in the intervention group, 41.6% showed elevated BNP levels at some point during the study. These patients received an echocardiogram and continued care under both their physicians and a specialist cardiology service. In addition to showing lower rates of the primary endpoint, intervention patients also had lower rates of emergency hospitalization for major cardiovascular events at 22.3 per 1,000 patient years compared to 40.4 per 1,000 patient years in the control group. The investigators found that a significantly lower number of patients in the intervention group than in the control group met the primary endpoint of new onset heart failure requiring hospitalization or left ventricular dysfunction.

Kenneth McDonald, MD, director of the Heart Failure Unit at St. Vincent's and a senior author of the study, said "Our study shows that a simple blood test screening, followed by targeted care of people at heightened risk of heart failure, can result in a dramatic reduction in cardiovascular events. This is good news, since heart failure has become a major public health problem and middle-aged adults today have a 20% to 30% lifetime risk of developing heart failure." The study was presented at the American College of Cardiology's 62nd Annual Scientific Session held March 9–11, 2013, in San Francisco (CA, USA).

Related Links:
St. Vincent's University Hospital



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.